Acuamark Diagnostics, Inc.

Happy 4th of July!

Acuamark is wishing everyone a safe and joyous Independence Day filled with celebration and pride. As we celebrate our nation’s freedom, it is important we reflect on the need for equity and healthcare accessibility for all.

According to a recent NPR report, 50% of U.S. military bases are situated in federally designated healthcare deserts. At Acuamark, we recognize the importance of developing early detection technologies that are cost effective and easily accessible, bridging these gaps and ensuring that our service members receive the care they deserve.

Together, let's innovate for health equity.

Join Acuamark's CEO at .

On Thursday, June 6, Bernard Peperstraete will speak on the panel “Competing as a Diagnostic Company in the Current Funding Environment: New Funding Models.”

We’re looking forward to an engaging discussion on the diagnostics industry's current funding landscape and new strategies for the future.

President Joe Biden has declared April 2024 as Cancer Prevention and Early Detection Month, urging citizens, government agencies, businesses, nonprofits, and other groups to raise awareness about cancer prevention, detection, and treatment. (bit.ly/3xuLKZH)

Despite significant progress, the fight against cancer continues. At Acuamark, we're developing novel technology for early cancer detection with our innovative technology. By detecting cancer-specific DNA methylation using PCR technology, we aim to revolutionize early detection, making it as accessible as in-clinic COVID tests.

Learn more about our work and stay updated: acuamarkdx.com

A Proclamation on National Cancer Prevention and Early Detection Month, 2024 | The White House Cancer has touched nearly every American family. During National Cancer Prevention and Early Detection Month, we honor the enormous courage and strength of the millions of Americans facing the disease today and of the many millions of survivors, whose resilience inspires us all. Together, we will en...

Join the American College of Gastroenterology (ACG) in recognizing "Dress in Blue Day" tomorrow, March 1, 2024, rallying the GI community to wear blue and show support for lifesaving colorectal cancer screening.

Early detection is key in the fight against colorectal cancer. At , we're dedicated to developing novel technologies for early cancer detection, aiming to unlock massive benefits for patients and society at large.

Discover resources developed by ACG experts on the College's website! Link in comments.

Today, we honor Dr. Martin Luther King Jr.'s work and legacy of justice, equality and acts of service. Inclusion is at the core of our mission, recognizing diversity as the driving force behind our innovation and success in the global fight against cancer. Together, we reflect on the dreams and values of Martin Luther King.

Meet Ezeddin Fadel, MD, our Clinical Research Manager of Biorepository.

Ezeddin shares his motivation for joining the AcuamarkDx team: "I worked in therapeutic oncology trials for more than 7 years. Although it is important to research viable cancer treatments, I am deeply committed to making a meaningful impact in the fight against cancer. The diagnostics field offers a unique opportunity to be at the forefront of cutting-edge medical technology for early cancer detection. And working at Acuamark is enabling me to be part of a team dedicated to pushing the boundaries of science and medicine to address this challenge."

Recent findings from UT Southwestern Medical Center highlight a crucial challenge in colorectal cancer screening: about 10% of at-home tests are unusable, mostly due to patient errors. This underscores the need for more reliable and cost-effective early detection methods.

At Acuamark, we're dedicated to developing simple, convenient and accurate blood-based cancer detection technologies. Early detection saves lives; our goal is to make it a standard part of primary care. Learn more about our mission and innovative approach at our website. Link in comments.

At-home colorectal cancer screenings pose challenges for some Despite the convenience of at-home screening tests for early detection of colorectal cancer (CRC), a study led by UT Southwestern Medical Center researchers examining more than a decade of patient data found that about 10% of the tests could not be processed, mostly due to patient error.

Wishing you a happy holiday season filled with joy and good health! As we reflect on the past year, we're so grateful for our team at Acuamark. Their hard work and commitment are critical to our mission of making early cancer detection the new standard of primary care, and we look forward to what's to come next year. Happy holidays from the Acuamark team!

Recent findings from UT Southwestern Medical Center highlight a crucial challenge in colorectal cancer screening: about 10% of at-home tests are unusable, mostly due to patient errors. This underscores the need for more reliable and cost-effective early detection methods.

At Acuamark, we're dedicated to developing simple, convenient and accurate blood-based cancer detection technologies. Early detection saves lives, and our goal is to make it a standard part of primary care. Learn more about our mission and innovative approach at acuamarkdx.com.

https://ow.ly/CWlV50QiSrY

At-home colorectal cancer screenings pose challenges for some Despite the convenience of at-home screening tests for early detection of colorectal cancer (CRC), a study led by UT Southwestern Medical Center researchers examining more than a decade of patient data found that about 10% of the tests could not be processed, mostly due to patient error.

"What will be funded is technology that makes a meaningful difference for patients and slashes the economic burden of care. Where there’s differentiated best-in-class tech, large market potential, and significant patient impact, deal activity will continue to flow."

In a recent feature for Life Science Leader, AcuamarkDx CEO Bernard Peperstraete shared his insights into the intricacies of the funding landscape for innovative early-stage companies.

Read more at the link in the comments.

Meet Marisa Debboli-Cop, CCRP, our Clinical Research Manager of Trial Ex*****on.

Marisa shares why joining AcuamarkDx's team was an easy choice for her: "I was inspired to join the AcuamarkDx team after learning more about the company’s mission and long-term goals. The opportunity to develop an accessible, accurate and cost-effective blood test for early detection of cancer would create a positive impact for patients across communities and backgrounds and revolutionize the healthcare landscape. The AcuamarkDx team’s dedication to this mission made it an easy choice to become a part of this endeavor and contribute in any way I can."

The Acuamark Diagnostics team is hard at work to make asymptomatic cancer screening and monitoring the gold standard of primary healthcare.

One challenge in early-stage cancer diagnostics is the inability to create a highly sensitive and specific test where the signal is low in abundance, like in early cancers. By optimizing qPCR technology to detect low-abundance methylation markers in early-stage cancer, we're advancing early detection that is both sensitive and specific – able to correctly identify patients with cancer and correctly identify those without cancer.

Follow our journey and learn more by visiting our website. Link in the comments.

Meet Stephanie McClure, our valued Human Resources Partner with The O'Connor Group.

Stephanie comments on AcuamarkDx's core values: "At AcuamarkDx, we believe that our people are our most valuable asset. We recognize that diverse backgrounds, opinions and capabilities create a stronger team. We’ve intentionally hired and built a diverse and dedicated group of professionals that embodies our core values of honesty, respect, innovation and compassion. This commitment is demonstrated in our day-to-day operations, and what excites me most is the big mission that AcuamarkDx is pursuing, supported by our brilliant and capable team committed to making this happen!"

Meet Priyanka Singh, our Clinical Research Manager of Auditing & Quality Assurance.

Priyanka highlights AcuamarkDx's mission: "AcuamarkDx’s main goal of creating early detection of 21 different types of cancer is profoundly exciting. With the ability to detect cancer at all stages, AcuamarkDx’s technology could save lives, promote cancer awareness and instill hope in everyone. AcuamarkDx is the future of diagnostics, and I believe we will ultimately have a significant impact in oncology.

"Moreover, AcuamarkDx demonstrates a strong commitment to diversity and inclusion through diverse hiring and recruitment practices and an inclusive workplace culture. At AcuamarkDx, voicing your opinions and ideas is encouraged and welcomed in a judgment-free environment."

Our CEO, Bernard Peperstraete, recently attended in NYC and had a remarkable experience connecting with fellow innovators and discussing AcuamarkDx's work. It left us feeling thoroughly inspired!​

Stay tuned for our updates – you can follow our journey on our website. And in case you missed it, read about us in ENMEDIA’s “Dx Companies On the Rise.” Link in comments. ​

Early detection can make all the difference in cancer survival. Shockingly, colorectal cancers are often detected at stage 3 or later, resulting in poor survival rates.

At , we're hard at work developing technology to unlock early cancer detection. Join us in underscoring the power of as a catalyst for societal impact.

Health equity means that every individual, regardless of their race, socioeconomic status, gender, sexual orientation, age, or geographic location, has an equal opportunity to achieve optimal health outcomes.

At , we envision a world where everyone has an equal opportunity for a healthy life regardless of their background. Health equity isn't merely a phrase to us—it's at the very core of our mission and the impact we strive for within our communities. We embrace diversity, recognizing it as the key to revolutionizing the global fight against .

Cancer screening recommendations can be puzzling. Let's clear up misconceptions about colorectal cancer screening with some truths from Mayo Clinic Health System: bit.ly/3sGVA89

Some highlights:
-Colorectal cancer is more common than you might think.
-Age isn't the only risk; younger people are getting diagnosed too.
-Family history isn't the sole factor; lifestyle choices play a role.

At AcuamarkDx we strongly believe early detection saves lives. That's why we're on a mission to develop accurate and cost-effective technology to make early cancer detection the new standard of primary care.

Visit our new website to learn more and stay up to date on our technology: https://acuamarkdx.com/

Top 4 myths around colorectal cancer screening: Learn the facts Colon cancer screening is rife with myth. Here are the facts about these truly lifesaving tests.

It is our mission to improve and democratize accurate early cancer screening by developing high-precision technology for early cancer detection.

https://acuamarkdx.com/

An article on Yahoo News highlights three superfoods that show promise in supporting cancer treatment. According to the article, broccoli, green tea, and turmeric possess potent anti-cancer properties and may have a positive impact on patient's well-being.

Read more: https://bit.ly/3O5TnvN

3 Superfoods for cancer treatment A bad diet can make it easier for different diseases to appear

This July, as we soak up the sun, let's prioritize our skin health. July is UV Safety Month, reminding us to protect our skin from harmful UV rays. Wear sunscreen, seek shade, and wear protective clothing to reduce your risk of skin cancer.